Design TherapeuticsDSGN
Market Cap: $264M
About: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Employees: 57
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 93 [Q1] → 95 (+2) [Q2]
1.57% more ownership
Funds ownership: 55.24% [Q1] → 56.81% (+1.57%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
15% less capital invested
Capital invested by funds: $126M [Q1] → $108M (-$18.3M) [Q2]
93% less call options, than puts
Call options by funds: $5K | Put options by funds: $75K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
RBC Capital Leonid Timashev 50% 1-year accuracy 14 / 28 met price target | 14%downside $4 | Sector Perform Reiterated | 6 Aug 2024 |